Skip to Main Content
Skip Nav Destination

Durvalumab Significantly Benefits SCLC Patients

April 5, 2024

In the global phase III ADRIATIC trial, AstraZeneca’s PD-L1 inhibitor durvalumab (Imfinzi) demonstrated significantly improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer (SCLC) whose disease did not progress following concurrent chemoradiotherapy (cCRT) compared with a placebo after cCRT; data will be presented at an upcoming medical meeting. A second arm of the trial is comparing the effectiveness of durvalumab monotherapy with durvalumab plus the CTLA4 inhibitor tremelimumab (Imjudo) in the same patient population. Durvalumab is approved in the United States and several other countries for the treatment of extensive-stage SCLC based on results of the phase III PACIFIC trial.

Close Modal

or Create an Account

Close Modal
Close Modal